respiratori
viral
infect
caus
mild
sever
diseas
common
cold
bronchiol
pneumonia
associ
substanti
burden
societi
test
new
molecul
shorten
allevi
diseas
develop
new
therapi
relev
human
vitro
model
mandatori
human
standard
airliquid
interfac
airway
epitheli
cultur
hold
vitro
specif
mechan
counter
invad
compar
vivo
situat
mucu
product
mucociliari
clearanc
secret
defens
molecul
object
studi
test
relev
model
discoveri
valid
antivir
drug
fulli
differenti
nasal
epithelium
cultur
inocul
picornavirus
coronaviru
influenza
virus
absenc
presenc
refer
antivir
drug
result
show
rupintrivir
effici
inhibit
replic
respiratori
picornavirus
dose
depend
manner
prevent
impair
mucociliari
clearanc
similarli
oseltamivir
reduc
replic
influenza
virus
dose
depend
manner
prevent
impair
epitheli
barrier
function
cytotox
day
infect
addit
found
rhinoviru
influenza
induc
signific
increas
defensin
cathelicidin
releas
differ
time
cours
result
reveal
larg
panel
epitheli
function
modifi
upon
viral
infect
valid
pertin
tool
preclin
antivir
drug
test
human
reconstitut
airway
epitheli
model
highli
relev
use
tool
pharmacolog
toxicolog
biolog
gener
sever
standard
model
commerci
avail
stratifi
along
respiratori
tract
nasal
tracheal
bronchial
recent
origin
small
airway
huang
et
al
wellvalid
human
vitro
model
contain
ciliat
goblet
basal
cell
repres
upper
airway
epithelia
huang
et
al
airway
epithelium
first
line
defenc
microb
provid
robust
conveni
platform
studi
viral
bacteri
infect
vitro
allow
dissect
molecular
cellular
mechan
hostpathogen
interact
constitut
also
platform
medium
throughput
test
therapeut
compound
upper
respiratori
infect
also
known
common
cold
mostli
caus
virus
major
infect
selflimit
howev
sever
complic
bronchiol
pneumonia
may
occur
particularli
children
elderli
patient
moreov
upper
respiratori
infect
wide
implic
acut
exacerb
cystic
fibrosi
asthma
chronic
obstruct
pulmonari
diseas
jackson
johnston
seemung
et
al
wat
et
al
among
respiratori
pathogen
virus
rhinovirus
respiratori
syncyti
virus
influenza
virus
high
preval
human
rhinovirus
rv
human
enterovirus
ev
belong
picornavirida
famili
nonenvelop
posit
sens
singl
strand
rna
virus
human
rhinovirus
divid
rva
rvb
rvc
speci
influenza
virus
belong
orthomyxovirida
famili
envelop
neg
sens
singl
strand
segment
rna
virus
human
coronavirus
hcov
belong
coronavirida
famili
envelop
posit
sens
singl
strand
rna
virus
season
respiratori
ill
present
substanti
burden
healthcar
worldwid
current
treatment
viral
respiratori
infect
support
case
use
antivir
drug
necessari
instanc
infant
highrisk
immunocompromis
patient
chronic
respiratori
diseas
thu
oseltamivir
zanamivir
peramivir
recommend
influenza
ribavirin
palivizumab
use
treat
prevent
respect
respiratori
syncyti
viru
infect
http
wwwcdcgovfluprofession
antiviralssummaryclinicianshtm
jha
et
al
howev
food
drug
administr
approv
antivir
avail
rhinovirus
enterovirus
coronavirus
caus
sever
acut
respiratori
middl
east
respiratori
syndrom
clearli
unmet
need
antivir
drug
moreov
test
antivir
agent
least
part
hamper
limit
number
relev
anim
model
virus
context
standard
nasal
human
epitheli
model
function
characterist
similar
vivo
situat
mucu
product
mucociliari
clearanc
secret
cytokin
chemokin
appear
suitabl
model
support
develop
new
antivir
aim
studi
evalu
valid
potenti
vitro
platform
develop
antivir
compound
respiratori
virus
purpos
refer
antivir
molecul
test
fulli
differenti
nasal
epithelium
cultur
inocul
target
respiratori
virus
addit
emphas
accuraci
mimic
vivo
situat
also
characteris
antimicrobi
respons
model
measur
respiratori
viru
induc
specif
releas
antimicrobi
peptid
studi
one
repres
rhinoviru
speci
well
repres
respiratori
enterovirus
chosen
inocul
cultur
rupintrivir
irrevers
inhibitor
human
rhinoviru
proteas
broad
antirhinovir
activ
zalman
et
al
despit
pass
phase
ii
clinic
trial
natur
infect
poor
pharmacokinet
properti
rupintrivir
consist
shown
antivir
activ
vitro
human
experiment
induc
rhinoviru
cold
hayden
et
al
patick
et
al
therefor
chosen
refer
drug
studi
influenza
genu
subtyp
use
studi
antivir
follow
recommend
advis
use
oseltamivir
neuraminidas
inhibitor
treat
prevent
influenza
infect
final
human
coronavirus
use
infect
refer
antivir
current
avail
strain
airway
cell
obtain
patient
undergo
surgic
polypectomi
experiment
procedur
explain
full
subject
provid
inform
consent
studi
conduct
accord
declar
helsinki
biomed
research
hong
kong
amend
receiv
approv
local
ethic
commiss
human
airway
epitheli
cell
isol
expand
two
passag
preserv
physiolog
characterist
cell
airway
epithelia
reconstitut
individu
donor
lessen
differ
donor
mixtur
human
airway
cell
differ
donor
viral
infect
airway
epithelia
reconstitut
mixtur
human
nasal
cell
isol
differ
donor
cultur
airliquid
interfac
ali
cultur
medium
readytous
chemic
defin
serumfre
epithelix
geneva
switzerland
plate
transwel
insert
cat
corn
incorpor
tweksburi
usa
model
stabl
month
gener
reproduc
data
sever
domain
toxicolog
therapeut
drug
studi
diseas
model
baxter
et
al
balogh
sivar
et
al
rocca
et
al
sonnevil
et
al
rhinoviru
rv
purchas
american
type
cultur
collect
manassa
usa
rhinoviru
influenza
influenza
isol
directli
clinic
specimen
previous
describ
essaidilaziosi
et
al
tapparel
et
al
influenza
lineag
determin
pcr
hemagglutin
inhibit
assay
partial
sequenc
close
refer
strain
viral
stock
experi
produc
collect
apic
wash
cultur
medium
product
sever
day
pool
quantifi
taqman
qpcr
aliquot
store
prior
infect
apic
side
cultur
wash
cultur
medium
transfer
new
plate
contain
cultur
medium
inocul
perform
cultur
medium
contain
differ
concentr
viru
appli
apic
side
cultur
h
three
concentr
inocul
test
preliminari
experi
supplementari
fig
noninfect
control
expos
also
cultur
medium
apic
side
h
age
cultur
vari
day
ali
virus
elimin
incub
period
three
rapid
wash
step
remain
virus
wash
verifi
min
apic
wash
quantifi
qpcr
rupintrivir
purchas
santa
cruz
biotechnolog
dalla
us
neuraminidas
inhibitor
oseltamivir
carboxyl
oseltamivir
obtain
carbosynth
compton
uk
drug
dilut
dmso
final
concentr
use
respect
antivir
ad
concomitantli
viral
inocul
basal
media
renew
along
infect
cultur
media
chang
everi
day
apic
wash
cultur
medium
perform
min
incub
h
day
rna
extract
apic
wash
qiaamp
viral
rna
kit
qiagen
tissu
rneasi
kit
qiagen
quantifi
quantit
rtpcr
qpcr
quantitect
probe
rtpcr
qiagen
taqman
abi
appli
biosystem
thermofish
scientif
waltham
us
primer
taqman
probe
well
amplif
paramet
describ
previous
essaidilaziosi
et
al
schibler
et
al
briefli
utr
region
amplifi
agc
ctg
cgt
gcc
kgc
c
forward
gaa
aca
cgg
aca
ccc
aaa
gta
gt
revers
primer
rhinovirus
gct
gcg
ytg
gcg
gcc
forward
gaa
aca
cgg
aca
ccc
aaa
gta
gt
revers
primer
enteroviru
influenza
viru
mp
gene
amplifi
gac
cra
tcc
tgt
cac
ctc
tga
c
forward
agg
gca
tti
tgg
aca
aak
cgt
cta
revers
primer
influenza
ns
gene
use
tcc
tca
ayt
cac
tct
tcg
agc
g
forward
cgg
tgc
tct
tga
cca
aat
tgg
revers
primer
coronaviru
gene
amplifi
stc
gat
cgg
gac
cca
agt
ag
forward
cct
tcc
tga
gcc
ttc
aat
ata
gta
acc
revers
primer
mdck
madindarbi
canin
kidney
cell
obtain
american
type
cultur
collect
manassa
us
cultur
dulbecco
modifi
eagl
medium
dmem
glutamax
thermofish
scientif
supplement
vv
fetal
bovin
serum
fb
pan
biotech
penicillin
streptomycin
gibco
hela
cell
obtain
american
type
cultur
collect
manassa
us
cultur
minimum
essenti
medium
eagl
mem
sigma
supplement
vv
fetal
bovin
serum
fb
lglutamin
gibco
fungizon
gibco
gentamycin
gibco
vancomycin
applichem
cultur
maintain
co
atmospher
infect
medium
mdck
similar
fb
wherea
hela
mccoy
gibco
supplement
fb
fungizon
vancomycin
gentamycin
mgcl
hanselar
ag
switzerland
viral
titer
influenza
sampl
determin
log
tcid
ml
endpoint
method
reed
muench
hela
mdck
cell
respect
flint
confluent
monolay
inocul
quadrupl
serial
dilut
viral
sampl
place
h
post
infect
cell
wash
phosphatebuff
salin
pb
fix
cold
methanol
aceton
min
permeabilis
pbstriton
fluka
infect
cell
immunostain
use
mous
antidsrna
antibodi
scicon
dilut
mous
antiinfluenza
antibodi
light
diagnost
dilut
antimous
hrp
link
secondari
antibodi
cell
signal
technolog
dilut
cell
incub
min
activ
substrat
sigma
dilut
deioniz
water
subsequ
wash
phosphatebuff
salin
pb
posit
well
score
light
microscop
addit
cultur
medium
apic
compart
tissu
cultur
resist
measur
across
cultur
evomx
voltohmmet
world
precis
instrument
sarasota
us
resist
valu
convert
teer
use
follow
formula
teer
resist
valu
x
cm
resist
membran
cm
total
surfac
epithelium
viru
induc
chang
present
percentag
noninfect
control
lactat
dehydrogenas
assay
basal
medium
incub
reaction
mixtur
cytotox
detect
kitplu
follow
manufactur
instruct
sigma
roch
st
loui
usa
determin
percentag
cytotox
follow
equat
use
absorb
valu
cytotox
exp
valu
low
control
high
control
low
control
high
control
valu
correspond
triton
treatment
appli
cultur
h
threshold
limit
toxic
index
reflect
physiolog
cell
turnov
cultur
polystyren
microbead
diamet
sigma
ad
apic
surfac
airway
cultur
movement
microbead
video
track
record
frame
per
second
imag
video
acquisit
setup
compos
soni
camera
connect
olympu
microscop
object
heat
microscop
plate
three
movi
taken
per
insert
averag
bead
veloc
calcul
imageproplu
softwar
human
cathelicidin
antimicrobi
peptid
camp
quantifi
basal
medium
apic
wash
accord
manufactur
instruct
cusabio
wuhan
cn
sampl
dilut
analysi
use
pure
camp
measur
fig
refer
antivir
inhibit
viral
product
dose
depend
manner
ab
rupintrivir
appli
basal
cultur
medium
concomitantli
rhinoviru
n
rna
quantifi
apic
sampl
collect
qpcr
express
genom
copi
numberml
time
postinocul
cd
tissu
viral
content
quantifi
qpcr
h
presenc
rupintrivir
follow
rhinoviru
inocul
n
e
time
cours
apic
viral
load
enteroviru
inocul
presenc
rupintrivir
n
fg
time
cours
apic
viral
load
influenza
influenza
inocul
presenc
oseltamivir
n
one
way
cd
twoway
anova
test
perform
multipl
comparison
p
p
p
p
data
present
mean
standard
error
mean
statist
comparison
oneway
twoway
analysi
varianc
perform
multipl
comparison
test
use
graphpad
prim
softwar
version
la
jolla
usa
p
p
p
p
preliminari
test
indic
rupintrivir
effici
inhibit
viral
product
ad
basal
medium
apic
side
inde
rupintrivir
administ
basal
concentr
rang
show
dosedepend
inhibit
fig
viral
product
regard
refer
antiinfluenza
compound
oseltamivir
administ
basal
medium
concentr
rang
mimic
human
therapeut
condit
mean
plasma
concentr
report
oral
administ
oseltamivir
davi
found
oseltamivir
treatment
reduc
fig
n
fig
n
influenza
viru
replic
dosedepend
manner
amplitud
reduct
result
oseltamivir
treatment
log
respect
h
importantli
effici
dose
antivir
rupintrivir
oseltamivir
show
toxic
effect
cultur
document
analysi
physiolog
function
noninfect
drug
treat
condit
ie
teer
fig
mucociliari
clearanc
fig
c
genom
copi
number
give
inform
infect
viral
yield
cell
culturebas
viru
titrat
perform
end
tissu
infect
dose
tcid
determin
common
cell
line
independ
seri
experi
carri
one
repres
viru
rhinoviru
treat
concentr
rupintrivir
one
repres
viru
influenza
treat
concentr
oseltamivir
base
genom
copi
number
result
infecti
titer
assess
apic
wash
collect
h
post
infect
tissu
inocul
sampl
hela
mdck
cell
line
comparison
genom
copi
number
infecti
titer
present
supplementari
fig
new
tcid
result
confirm
antivir
efficaci
rupintrivir
oseltamivir
first
observ
genom
copi
number
quantif
result
show
gener
pattern
antivir
induc
dosedepend
inhibit
quit
similar
two
method
howev
decay
viral
particl
highest
antivir
dose
seem
mark
estim
cell
culturebas
method
rather
molecular
method
addit
rough
estim
rupintrivir
ic
gave
base
genom
copi
number
quantif
use
tcid
method
similarli
ic
oseltamivir
influenza
estim
nm
genom
copi
number
tcid
although
limit
number
antivir
dilut
permit
establish
confid
ic
valu
result
suggest
differ
sensit
two
method
inhibit
amplif
sever
antivir
among
chloroquin
test
none
effici
model
chloroquin
appli
concentr
basal
medium
show
cytotox
highest
concentr
report
microscop
observ
ldh
assay
h
supplementari
fig
measur
transepitheli
electr
resist
teer
rapid
noninvas
method
assess
tissu
integr
addit
teer
highli
dynam
paramet
sensit
variou
stimuli
teer
valu
measur
cultur
typic
fell
cm
teer
valu
show
substanti
revers
repres
teer
cytotox
percentag
e
threshold
limit
valu
cytotox
correspond
physiolog
cell
turnov
long
term
cultur
oneway
anova
test
perform
daili
multipl
comparison
p
p
p
p
irrevers
modif
teer
valu
cm
consid
low
chang
may
yet
revers
loss
tissu
integr
correspond
teer
cm
epithelium
serious
damag
decreas
teer
associ
increas
ldh
releas
cytotox
assay
decreas
cell
viabil
long
term
cultur
physiolog
cell
turnov
show
maximum
cytotox
cell
replac
signific
increas
cytotox
associ
decreas
teer
therefor
teer
cytotox
measur
simultan
compar
antivir
efficaci
differ
viru
infect
teer
valu
present
percentag
noninfect
control
cultur
among
test
rhinovirus
induc
teer
diminut
cm
show
control
h
n
p
control
h
p
fig
without
increas
ldh
releas
data
shown
interestingli
teer
fulli
restor
h
valu
even
higher
control
suggest
epithelium
abl
recov
damag
induc
within
short
period
time
teer
chang
prevent
rupintrivir
treatment
n
produc
moder
decreas
teer
reach
level
signific
contrast
influenza
virus
caus
decreas
teer
cm
h
reach
control
n
p
control
respect
fig
c
n
p
teer
diminut
prevent
dose
depend
manner
antivir
oseltamivir
n
induc
tissu
disrupt
start
h
result
teer
control
n
p
associ
signific
cytotox
demonstr
increas
ldh
releas
reach
toxic
index
p
compar
noninfect
control
fig
e
teer
ldh
valu
remain
affect
time
teer
p
ldh
p
h
teer
p
ldh
p
suggest
spontan
repair
case
influenza
infect
observ
time
window
four
day
postinocul
note
rupintrivir
oseltamivir
treatment
induc
signific
chang
teer
fig
ldh
releas
fig
point
lack
toxic
two
drug
cultur
mucociliari
clearanc
mcc
primari
defenc
mechan
move
away
pathogen
particl
respiratori
airway
function
finetun
quantiti
qualiti
mucu
product
well
number
cilia
synchron
beat
measur
mcc
infect
microbead
ad
apic
surfac
epithelia
video
taken
order
measur
veloc
movement
mention
mcc
determin
variou
paramet
highli
depend
temperatur
mean
mcc
rang
noninfect
cultur
signific
mucociliari
clearanc
chang
observ
follow
infect
n
n
respect
contrast
infect
caus
strong
decreas
mcc
h
compar
noninfect
control
n
p
complet
arrest
h
vs
control
p
fig
reduct
accompani
cytotox
data
shown
note
addit
rupintrivir
cultur
media
effici
prevent
dramat
effect
mcc
fig
prevent
effect
rupintrivir
also
observ
infect
counteract
dose
depend
manner
decreas
mcc
vs
control
n
p
measur
h
room
temperatur
fig
similar
way
found
oseltamivir
effici
prevent
mcc
arrest
vs
control
n
measur
h
infect
fig
rupintrivir
oseltamivir
alon
modifi
significantli
mcc
fig
c
recent
shown
essaidilaziosi
et
al
follow
viral
infect
epitheli
cell
vivo
counterpart
releas
multitud
chemokin
cytokin
local
inflamm
reaction
effici
prevent
antivir
dose
depend
manner
supplementari
fig
howev
anoth
import
primari
innat
host
defenc
mechan
airway
epitheli
cell
product
antimicrobi
peptid
amp
inde
epitheli
cell
synthes
secret
amp
either
constitut
induc
upon
viral
bacteri
infect
hariri
cohen
measur
elisa
assay
apic
basal
secret
defensin
cathelicidin
repres
two
main
respiratori
epithelium
amp
class
differ
viral
infect
noninfect
cultur
constitut
secret
ngml
measur
either
basal
apic
fig
quantiti
significantli
increas
infect
vs
ngml
noninfect
p
apic
side
follow
infect
side
cultur
h
b
mcc
measur
h
room
temperatur
follow
enteroviru
inocul
absenc
presenc
antivir
rupintrivir
n
c
mcc
measur
h
follow
influenza
inocul
absenc
presenc
antivir
oseltamivir
n
oneway
anova
test
perform
daili
multipl
comparison
p
p
p
p
postinocul
apic
vs
noninfect
p
basal
vs
ngml
noninfect
p
similarli
influenza
induc
huge
increas
secret
apic
basal
side
cultur
apic
vs
ngml
control
basal
vs
ngml
control
fig
contrast
upregul
secret
overal
rupintrivir
oseltamivir
antivir
inhibit
product
induc
viral
infect
regard
cathelicidin
camp
secret
significantli
induc
side
cultur
h
infect
influenza
fig
signific
quantiti
camp
detect
noninfect
control
cultur
camp
apic
concentr
increas
ngml
infect
p
ngml
follow
influenza
infect
n
p
basal
secret
increas
ng
ml
p
ngml
influenza
n
p
time
point
h
rupintrivir
oseltamivir
antivir
prevent
product
camp
treat
cultur
howev
camp
secret
profil
chang
time
h
infect
camp
detect
apic
side
inocul
cultur
level
still
high
ngml
n
p
basal
side
fig
high
level
camp
also
detect
basal
side
rupintrivir
cultur
ngml
contrast
protect
effect
previous
observ
rupintrivir
h
influenza
condit
h
observ
strong
induct
camp
apic
basal
side
cultur
ng
ml
ngml
respect
similarli
rupintrivir
oseltamivir
prevent
camp
secret
report
high
concentr
measur
compart
influenza
oseltamivir
cultur
apic
ngml
basal
ngml
disabl
result
upper
respiratori
infect
mostli
caus
virus
common
cold
bronchiol
pneumonia
repres
import
cost
societi
test
new
molecul
intend
shorten
allevi
patholog
develop
new
antivir
approach
relev
human
model
clearli
mandatori
due
speci
well
cellular
tropism
viru
studi
respiratori
infect
tradit
cell
line
undifferenti
monolay
epitheli
cell
submerg
cultur
use
could
nt
replic
faith
real
mechan
viral
infect
human
respiratori
tract
therefor
increas
number
studi
turn
recent
toward
ali
model
high
physiolog
function
relev
investig
certain
aspect
respiratori
viral
infect
berman
et
al
farsani
et
al
grigg
et
al
jone
et
al
studi
undertook
rather
holist
analysi
physiolog
modif
happen
human
airway
ali
cultur
upon
viral
infect
reveal
import
innat
immun
respons
viru
strain
depend
refer
antivir
effici
inhibit
viral
replic
cultur
assess
two
independ
viru
quantif
method
genom
copi
number
determin
infecti
viru
titer
obtain
tcid
moreov
establish
cultur
allow
screen
rank
antivir
overal
data
support
use
standard
airway
promis
preclin
model
design
test
novel
antivir
strategi
comparison
airliquid
interfac
approach
berman
et
al
farsani
et
al
grigg
et
al
jone
et
al
made
low
passag
human
airway
epitheli
cell
ensur
maximum
similar
physiolog
condit
reconstruct
standard
qualiti
control
use
function
test
import
asset
preclin
test
alreadi
address
absorpt
studi
demonstr
capac
model
predict
respiratori
transport
human
reu
et
al
xenobiot
metabol
gene
profil
demonstr
strong
correspond
normal
human
lung
activ
confirm
baxter
et
al
suggest
high
function
similar
vivo
situat
oneway
anova
test
perform
daili
multipl
comparison
p
p
p
p
studi
found
level
differ
respiratori
viru
product
compar
human
infect
condit
chiu
et
al
esposito
et
al
kennedi
et
al
ngaosuwankul
et
al
differ
viru
shed
kinet
inde
earli
rapid
phase
viru
replic
notic
steadi
state
viru
product
cultur
long
term
persist
viru
product
may
result
combin
two
factor
limit
number
infect
cell
previous
demonstr
immunocytochemistri
essaidilaziosi
et
al
well
absenc
immun
cell
model
possibl
explan
limit
viru
spread
observ
upregul
specif
antimicrobi
peptid
report
well
induct
releas
specif
cytokin
chemokin
essaidilaziosi
et
al
note
vitro
result
frame
human
situ
local
studi
show
small
proport
epitheli
cell
infect
rhinovirus
upper
lower
airway
arruda
et
al
mosser
et
al
nasal
epitheli
cell
compos
connect
togeth
via
cell
junction
known
desmosom
adheren
tight
junction
form
physic
barrier
inhal
pathogen
irrit
allergen
thu
mimick
vivo
situat
found
lead
loss
barrier
function
epitheli
tissu
earlier
time
point
infect
result
agreement
data
report
vitro
bronchial
epitheli
cell
line
vivo
mice
rv
infect
reduc
teer
dissoci
zona
tight
junction
complex
ecadherin
adheren
junction
sajjan
et
al
yeo
jang
interestingli
notic
loss
integr
transient
sinc
teer
restor
time
due
spontan
repair
epithelium
howev
barrier
dysfunct
fulli
prevent
rupintrivir
treatment
therefor
might
use
limit
exacerb
infect
convers
found
influenza
virus
induc
tissu
disrupt
revers
certainli
high
cytotox
caus
virus
reveal
high
ldh
releas
inde
overact
innat
immun
respons
excess
product
reactiv
oxygen
speci
document
influenza
condit
caus
acut
lung
injuri
imai
et
al
mucociliari
clearanc
mcc
primari
function
elimin
microb
airborn
particl
ciliat
cell
gener
synchron
movement
periciliari
fluid
viscou
viscou
mucu
gel
layer
lie
compos
secret
glycosyl
mucin
protein
sticki
mucu
trap
pathogen
cilia
move
away
major
viru
strain
test
studi
influenza
caus
mcc
impair
except
mcc
disrupt
consequ
perturb
highli
complex
multicompon
system
cilia
blockag
desynchron
modif
periciliari
fluid
layer
chang
viscoelast
mucu
etc
gizurarson
precis
reason
mcc
dysfunct
caus
type
viru
known
clearli
relat
cell
tropism
differ
respiratori
virus
use
studi
dijkman
et
al
essaidilaziosi
et
al
importantli
absenc
antivir
treatment
spontan
restor
mcc
detect
even
day
initi
inocul
decreas
mcc
particularli
favour
secondari
bacteri
infect
pittet
et
al
reliev
symptom
caus
viral
infect
would
benefici
restor
mucociliari
clearanc
epitheli
cell
also
gener
secret
antimicrobi
peptid
directli
interact
pathogen
two
major
class
amp
present
human
respiratori
airway
defensin
cathelicidin
compound
wide
rang
antivir
effect
includ
directli
attack
virus
inhibit
viral
entri
prevent
viral
replic
tripathi
et
al
wilson
et
al
amp
multipl
function
relat
abil
disrupt
membran
also
function
also
potent
immun
regul
lai
gallo
studi
provid
first
time
best
knowledg
detail
character
human
amp
upregul
measur
human
nasal
epithelium
model
upon
variou
respiratori
viru
infect
first
found
upregul
rhinoviru
influenza
measur
day
postinocul
result
perfect
agreement
level
measur
vivo
experiment
infect
healthi
adult
proud
et
al
studi
express
report
significantli
elev
day
relat
symptom
score
cultur
observ
presenc
antivir
level
induct
lower
induct
occur
investig
need
determin
modif
amp
level
antivir
posit
neg
effect
cours
infect
second
found
camp
upregul
time
cours
depend
viru
strain
induc
camp
concentr
reach
maximum
two
day
postinocul
apic
side
basal
camp
concentr
remain
stabl
time
influenza
induc
secret
camp
show
slower
kinet
maximum
concentr
reach
four
day
postinfect
apic
basal
howev
secret
camp
import
basal
compart
apic
side
possibl
explan
accumul
amp
basal
site
result
transient
persist
disrupt
epithelium
barrier
hand
specul
differ
time
cours
apic
basal
releas
may
reflect
dual
function
camp
innat
immun
earli
direct
action
microb
apic
side
later
immun
regulatori
action
via
recruit
activ
immun
cell
basal
side
taken
togeth
result
underscor
import
complex
host
innat
immun
respons
work
summari
result
demonstr
human
nasal
airway
epithelium
reconstitut
vitro
effici
tool
antivir
drug
develop
model
could
use
singl
multipl
viral
infect
viral
bacteri
coinfect
develop
evalu
antivir
respons
use
diseas
epithelia
base
donor
stratif
asthma
copd
envis
